XNAS · Healthcare · Diagnostics & Research
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.27 | -0.29 | -7.41% | $15.5M | ❌ Miss | -3.67% | +12.02% | — |
| 2026-02-26 | Q4 2025 | -0.29 | -0.26 | +10.34% | $17.3M | ✅ Beat | -8.08% | -5.20% | -29.79% |
| 2025-11-04 |
| Q3 2025 |
| -0.28 |
| -0.24 |
| +14.29% |
| $14.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -0.25 | -0.23 | +8.00% | $17.2M | ✅ Beat | -22.16% | -18.97% | -9.75% |
| 2025-02-27 | Q4 2024 | -0.28 | -0.23 | +17.86% | $16.8M | ✅ Beat | -2.36% | -0.47% | -17.22% |
| 2024-11-06 | Q3 2024 | -0.35 | -0.64 | -82.86% | $25.7M | ❌ Miss | -22.58% | -14.87% | -25.63% |
| 2024-08-07 | Q2 2024 | -0.37 | -0.24 | +35.14% | $22.6M | ✅ Beat | +19.10% | +54.86% | +86.46% |
| 2024-05-08 | Q1 2024 | -0.41 | -0.26 | +36.59% | $19.5M | ✅ Beat | +5.43% | -8.63% | -13.74% |
Showing last 8 quarters.